Case report · PMID 41669704
A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1 — VialBase Research
Nasopharyngeal carcinoma patient developed multisystem irAEs after sintilimab + Ta1
Last updated · 2026 · Li T, Wu BL, Yu CL, Jin LY · Clin Case Rep
Key findings
- Nasopharyngeal carcinoma patient developed multisystem irAEs after sintilimab + Ta1
- Presented with high fever, rash, interstitial pulmonary edema, multiple organ failure
- Highlights risk of immune overactivation when combining ICI + immunomodulators
Multisystemic irAE from Sintilimab + Ta1 (PMID: 41669704)
Case Summary
- Patient: nasopharyngeal carcinoma
- Treatment: sintilimab (PD-1 inhibitor) + thymosin alpha-1
- Adverse events: high fever, rash, interstitial pulmonary edema, multiple organ failure
- Outcome: managed with treatment discontinuation and supportive care
Clinical Significance
This case highlights the critical safety concern of combining Thymosin-Alpha-1 with immune checkpoint inhibitors. While Ta1 is generally safe in monotherapy, its immune-enhancing effects can synergize dangerously with ICI-mediated immune disinhibition, producing severe multi-organ irAEs.
Takeaway
Ta1 + ICI combinations require careful monitoring. The immune-boosting properties that make Ta1 effective for infections and cancer adjunct therapy become a liability when combined with checkpoint blockade that removes immune brakes.
See Also
- Parent compound: Thymosin-Alpha-1
Where to buy Thymosin Alpha-1
Thymosin Alpha-13 vetted vendors
BioLongevity LabsVisit BioLongevity Labs →
Save 15% with code VIALBASE
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.